摘要
目的分析增殖型糖尿病视网膜病变采用雷珠单抗联合激光治疗的临床疗效。方法选取我院2018年8月~2019年10月收治的100例(142眼)增殖型糖尿病视网膜病变患者为研究对象,随机分为两组,对照组患者单独采用激光治疗,观察组在对照组基础上联合雷珠单抗治疗,对比两组治疗前后最佳矫正视力(BCVA)、黄斑中心凹厚度(CMT)、眼压变化情况。结果与对照组对比,观察组治疗1个月后、治疗3个月后以及治疗6个月后的BCVA、CMT、眼压均更低(P<0.05)。结论增殖型糖尿病视网膜病变采用雷珠单抗联合激光治疗的临床疗效显著,利于改善患者的BCVA、CMT与眼压,值得推广。
Objective To analyze the clinical effect of the treatment of proliferative diabetic retinopathy with leizhumab and laser.Methods A total of 100 patients(142 eyes)with proliferative diabetic retinopathy admitted to our hospital from August 2018 to October 2019 were randomly divided into two groups.The patients in the control group were treated with laser alone.The observation group was treated with leizhumab on the basis of the control group.The changes of BCVA,CMT and IOP were compared before and after treatment Situation.Results Compared with the control group,the BCVA,CMT and IOP of the observation group were lower after 1 month,3 months and 6 months(P<0.05).Conclusion The clinical effect of the treatment of proliferative diabetic retinopathy with leizhumab combined with laser is significant,which is beneficial to the improvement of BCVA,CMT and intraocular pressure,and it is worth popularizing.
作者
梁静
Liang Jing(Ophthalmology,Shenzhen Hospital,Southern Medical University,Shenzhen,Guangdong Province)
出处
《首都食品与医药》
2020年第14期42-43,共2页
Capital Food Medicine
